Literature DB >> 17970053

VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer: relationships to clinicopathological parameters and long-term survival.

Edwin Herrmann1, Elke Eltze, Stefan Bierer, Thomas Köpke, Tobias Görge, Jorg Neumann, Lothar Hertle, Christian Wülfing.   

Abstract

BACKGROUND: Our aim was to determine the role of the lymphangiogenic markers VEGF-C, VEGF-D and Flt-4 in transitional bladder cancer.
MATERIALS AND METHODS: Archival cystectomy tumor blocks of 286 patients were selected for construction of a tissue microarray (TMA). Paraffin sections were assessed immunohistochemically using polyclonal antibodies against VEGF-C, VEGF-D and Flt-4. Staining results were evaluated semiquantitatively and analyzed for their association with various clinicopathological factors.
RESULTS: There was no association of VEGF-C with histopathological parameters or clinical outcome. Patients with VEGF-D overexpression had higher pathological tumor stages (p =0.021) and regional lymph node metastasis (p=0.008). Furthermore, they had a significantly reduced disease-free survival (p=0.042). Overexpression of Flt-4 was particularly present in the subgroup of G3 and G4 tumors (p=0.001) and was associated with a shorter disease-free survival (p=0.041). In multivariate analysis, only tumor stage and lymph node metastasis were independent prognostic parameters.
CONCLUSION: Targeting VEGF-D and Flt-4 could be a useful tool to predict and control progression of bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17970053

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  15 in total

Review 1.  Biomolecular predictors of urothelial cancer behavior and treatment outcomes.

Authors:  Michael Rink; Eugene K Cha; David Green; Jens Hansen; Brian D Robinson; Yair Lotan; Arthur I Sagalowsky; Felix K Chun; Pierre I Karakiewicz; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

Review 2.  [Value of biomarkers in urology].

Authors:  P J Goebell; B Keck; S Wach; B Wullich
Journal:  Urologe A       Date:  2010-04       Impact factor: 0.639

3.  Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells.

Authors:  Yuan Li; Xiaoping Yang; Lih-Jen Su; Thomas W Flaig
Journal:  Urology       Date:  2011-04-29       Impact factor: 2.649

4.  Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.

Authors:  Elizabeth A Beierle; Xiaojie Ma; Jerry E Stewart; Michael Megison; William G Cance; Elena V Kurenova
Journal:  Mol Carcinog       Date:  2012-10-12       Impact factor: 4.784

5.  Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.

Authors:  Jerry E Stewart; Xiaojie Ma; Michael Megison; Hugh Nabers; William G Cance; Elena V Kurenova; Elizabeth A Beierle
Journal:  Mol Carcinog       Date:  2013-07-19       Impact factor: 4.784

6.  Expression of vascular endothelial growth factor C in human pterygium.

Authors:  Junichi Fukuhara; Satoru Kase; Tsutomu Ohashi; Ryo Ando; Zhenyu Dong; Kousuke Noda; Takeshi Ohguchi; Atsuhiro Kanda; Susumu Ishida
Journal:  Histochem Cell Biol       Date:  2012-08-23       Impact factor: 4.304

7.  VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab.

Authors:  Markus Moehler; Christian Frings; Annett Mueller; Ines Gockel; Carl-C Schimanski; Stefan Biesterfeld; Peter-R Galle; Martin-H Holtmann
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

8.  VEGF receptors and neuropilins are expressed in the urothelial and neuronal cells in normal mouse urinary bladder and are upregulated in inflammation.

Authors:  Marcia R Saban; Joseph M Backer; Marina V Backer; Julie Maier; Ben Fowler; Carole A Davis; Cindy Simpson; Xue-Ru Wu; Lori Birder; Michael R Freeman; Shay Soker; Robert E Hurst; Ricardo Saban
Journal:  Am J Physiol Renal Physiol       Date:  2008-05-07

9.  CCL21/CCR7 up-regulate vascular endothelial growth factor-D expression via ERK pathway in human non-small cell lung cancer cells.

Authors:  Limei Sun; Qingfu Zhang; Yang Li; Na Tang; Xueshan Qiu
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

Review 10.  Guidelines for development of diagnostic markers in bladder cancer.

Authors:  Peter J Goebell; Susan L Groshen; Bernd J Schmitz-Dräger
Journal:  World J Urol       Date:  2008-02-06       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.